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Abstract
Background: Less than one-third of patients who are estimated to be infected with multidrug-resistant
tuberculosis (MDR-TB) receive MDR-TB treatment regimens, and only 48% of those who received treatment have
successful outcomes. Despite current regimens, newer, more effective and cost-effective approaches to treatment
are needed. The aim of the study was to project health outcomes and impact on healthcare resources of adding
bedaquiline to the treatment regimen of MDR-TB in selected high burden countries: Estonia, Russia, South Africa,
Peru, China, the Philippines, and India.
Methods: This study adapted an existing Markov model to estimate the health outcomes and impact on total
healthcare costs of adding bedaquiline to current MDR-TB treatment regimens. A price threshold analysis was
conducted to determine the price range at which bedaquiline would be cost-effective.
Results: Adding bedaquiline to the background regimen (BR) resulted in increased disability-adjusted life years
(DALYs) averted, and reduced total healthcare costs (excluding treatment acquisition costs) compared with BR
alone in all countries analyzed. Addition of bedaquiline to BR resulted in savings to healthcare costs compared with
BR alone in all countries analyzed, with the highest impact expected in Russia (US$194 million) and South Africa
(US$43 million). The price per regimen at which bedaquiline would be cost-effective ranged between US$23,904-
US$203,492 in Estonia, Russia, Peru, South Africa, and China (high and upper middle-income countries) and
between US$6,996-US$20,323 in the Philippines and India (lower middle-income countries); however, these
cost-effective prices do not necessarily address concerns about affordability.
Conclusions: Adding bedaquiline to BR provides improvements in health outcomes and reductions in healthcare
costs in high MDR-TB burden countries. The range of prices per regimen for which bedaquiline would be
cost-effective varied between countries.
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Background
Multidrug-resistant tuberculosis (MDR-TB), defined as
tuberculosis caused by strains resistant to isoniazid and
rifampicin, poses challenges to global TB control. Exten-
sively drug-resistant TB (XDR-TB), caused by MDR-TB
strains that are also resistant to any fluoroquinolone and
to at least one of the three injectable second-line drug
classes (aminoglycosides, polypeptides, fluoroquinolones,
thioamides, cycloserine, and para-aminosalicyclic acid)
[1] may result in even poorer outcomes compared with
MDR-TB [2]. In 2013, it was estimated that 3.5% of
newly-diagnosed and 20.5% of previously treated TB
cases had MDR-TB, and XDR-TB accounted for 9.0% of
all MDR-TB cases [2]. Prompt diagnosis of MDR-TB
and initiation of appropriate therapy provide the best
chance of favorable treatment outcomes [3].
Bedaquiline received accelerated and conditional ap-
proval in the United States and Europe, respectively, for
the treatment of pulmonary MDR-TB in combination with
other anti-tuberculosis drugs when an effective treatment
regimen cannot otherwise be provided [4, 5]. The World
Health Organization (WHO) subsequently issued interim
guidance for use of bedaquiline in adult patients with
pulmonary MDR-TB [6].
A study commissioned by the WHO previously ex-
plored the cost-effectiveness (CE) of adding bedaqui-
line to 20 month MDR-TB treatment regimens in six
low- to middle-income settings (Russia, Estonia, the
Philippines, Peru, Nepal, and China) [7], covering 17%
of global MDR-TB burden in 2013 [2]. The WHO
study showed that although bedaquiline was likely to be
cost-effective and cost-saving in Peru, Russia, Estonia, The
Philippines, and China, where treatment and management
costs are moderate to high, it may not be cost-effective in
low-income countries with low drug costs, such as Nepal
[7, 8]. Using a model with a longer time horizon [9], the
current study assessed the health outcomes and impact on
healthcare costs of using bedaquiline in seven countries,
including China, India and South Africa, where MDR-
TB has been reported to be highly prevalent; collect-
ively, the seven countries analyzed in the current study
accounted for approximately 60% of the global MDR-
TB burden in 2013 [2]. Nepal was not included in the
current study due to lack of available data at the time
of the analysis (including data related to country-
specific epidemiology, treatment pathways and health-
care costs).
Objectives
The primary objective of the study was to evaluate
health outcomes, expressed in terms of disability-
adjusted life years (DALYs) averted, following addition
of bedaquiline to the background regimen (BR) in the
treatment of MDR-TB in an economically diverse group
of high MDR-TB burden countries (Estonia, Russia, South
Africa, Peru, China, the Philippines, and India) (Additional
file 1: Table S1). The potential impact of adding bedaqui-
line on total healthcare costs was also assessed. An ex-
ploratory price analysis was conducted to estimate the
likelihood of bedaquiline being cost-effective as measured
by cost per DALY in each country setting, based upon
thresholds provided by the WHO [6]. It was not possible
to conduct a full CE analysis on the use of bedaquiline for
the treatment of MDR-TB because, at the time of the
analysis, there were no publicly listed prices for bedaqui-
line in the selected countries.
Methods
Model overview
A previously-described, cohort-based Markov state tran-
sition model [9] was adapted to evaluate the health and
economic benefits of adding bedaquiline to a BR com-
pared with BR alone, for the treatment of patients with
MDR-TB from the healthcare system perspective of
seven countries with a high MDR-TB burden: Estonia,
Russia, South Africa, Peru, China, the Philippines, and
India [2].
Health outcomes and healthcare costs were simulated
over a 10-year time horizon to capture downstream
consequences of treatment. The effectiveness of treat-
ment was evaluated in terms of DALYs averted. Defini-
tions of clinical and outcome data were sourced from
the literature [10, 11].
Model structure
The analysis included new laboratory-confirmed cases of
MDR-TB from each of the selected high MDR-TB
burden countries. Details of the model structure are de-
scribed in Wolfson et al. [9]. In brief, patients entered
the model in the “Active MDR-TB” or “Active XDR-TB”
states, depending on their level of resistance and would
experience slightly different clinical pathways (Fig. 1).
Patients could transition in 28-day cycles in the model
through health states such as sputum culture conver-
sion, treatment completion, loss to follow-up, and death.
The aim of treatment was to achieve sputum culture
conversion (transition to sputum culture converted
MDR-TB), and maintain the converted state until treat-
ment completion and assumed cure of MDR-TB (transi-
tion to treatment completion). All patients who culture
converted would transition to the cured health state
until they had completed treatment or relapsed. Once
treatment would be completed, patients would transition
to the completed and cured health state. Patients faced
different mortality risks depending on the status of their
culture conversion (1.22% before culture conversion,
0.18% following culture conversion, and all-cause mor-
tality once they completed treatment and were cured).
Lu et al. BMC Health Services Research  (2017) 17:87 Page 2 of 12
Treatment failures in the model consisted of patients
who relapsed (defined as having a positive sputum culture
after achieving sputum culture conversion) [12, 13], had a
recurrence of TB (defined as developing active TB after
treatment completion), or remained sputum culture posi-
tive after 1 year of treatment. Patients with MDR-TB who
failed treatment or relapsed could develop additional
resistance and experience XDR-TB.
Patients could become lost to follow-up (default)
anytime while on treatment. Patients initially diagnosed
with XDR-TB (‘Active XDR-TB’ state) could experience
similar outcomes (relative disability weight of 1.20 for
XDR-TB) to those initially diagnosed with MDR-TB
except that no subsequent treatment was allowed due
to the limited treatment options in this more severe
patient group. Patients with XDR-TB who failed treat-
ment transitioned to end of life care (palliative care),
where they experienced higher mortality and worse
health outcomes.
Clinical data
Data on the efficacy of treatment and the risk of morbidity
and mortality in patients with MDR-TB were obtained
from various sources, including the C208 study - a
Phase II, placebo-controlled, randomized trial of beda-
quiline in newly diagnosed MDR-TB patients [12, 13].
In addition, country-specific outcomes were also used
for the analysis [14, 15].
Comparative data were sourced in the form of hazard
ratios (HRs) from published clinical trial data [13] (Table 1)
Fig. 1 Outline of the Markov model assessing health outcomes of bedaquiline in high burden countries Source: adapted from [9] CE: cost-effectiveness;
MDR-TB: multidrug-resistant tuberculosis; XDR-TB: extensively drug-resistant tuberculosis. Note: MDR-TB population includes patients with MDR-TB as well
as XDR-TB patients; transitions to the death state are possible from every state, but not shown on the diagram for clarity
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and applied to data for patients receiving BR only to
estimate relative treatment effect.
Rates of sputum culture conversion for patients receiv-
ing BR treatment alone were estimated from a post-hoc
patient-level analysis of published clinical data from the
C208 study [12, 13]. The cumulative probability of
remaining sputum culture positive was split into three
time periods (<8 weeks, 8–24 weeks, and >24 weeks),
based on the best fit of survival probabilities observed in
the placebo arm of a bedaquiline clinical trial [13]. A
log-normal distribution was fitted to each period to
derive rates for the entire model time horizon (Table 1).
The HR on sputum culture conversion for bedaquiline
compared with BR was applied for the duration of beda-
quiline treatment (i.e. 24 weeks), after which patients were
assumed to experience no further reduction in the rate of
sputum culture conversion. The HR on sputum culture
conversion for patients with XDR-TB was generated based
on proxy data from patients with pre-XDR-TB collected in
an open-label bedaquiline study [13]; this was applied onto
the time-to-sputum culture conversion curves to estimate
the sputum culture conversion rates for XDR-TB patients.
Outcomes data
Disability adjusted life years (DALY), and years of life
lost due to premature mortality were sourced from two
sources: a global burden of disease study that reported
disability weights for active TB and the UK life tables
[16, 17]. The disability weight for treatment completion
was assumed to be zero (i.e. no disability).
Cost data
Cost data were sourced from country-specific databases
[18–23], hospitals, and scientific opinion leaders, as well
as published literature [8, 24–26]. Direct medical costs,
treatment monitoring costs, and administered care
(hospitalization and outpatient) costs were included in
the model (Table 2). It was assumed that 100% of pa-
tients were hospitalized until sputum culture conversion
(except for Estonia, India, and South Africa, where 80%,
5%, and 10%, respectively, of patients with MDR-TB
were hospitalized with those not hospitalized assumed
to have received outpatient care), after which they would
receive outpatient care only. Treatment acquisition costs
for bedaquiline were excluded from the cost analysis
Table 1 Disease transition probabilities for the high burden countries analyzed
Parameter Probability of event/28 days, % (SE) [Source]
Sputum culture conversion on BR, 0–8 weeks (log-normal)
Scale parameter 4.99 (0.21) Placebo-controlled phase II clinical trial C208 [12]
Shape parameter 0.73 (0.11) Placebo-controlled phase II clinical trial C208 [12]
Sputum culture conversion on BR, 8–24 weeks (log-normal)
Scale parameter 5.68 (0.40) Placebo-controlled phase II clinical trial C208 [12]
Shape parameter 1.90 (0.27) Placebo-controlled phase II clinical trial C208 [12]
Sputum culture conversion on BR, ≥24 weeks (log-normal)
Scale parameter 8.28 (1.09) Placebo-controlled phase II clinical trial C208 [12]
Shape parameter 2.70 (0.82) Placebo-controlled phase II clinical trial C208 [12]
Subsequent MDR-TB
Hazard ratio of subsequent MDR-TB (vs. initial MDR-TB) 0.54 (0.17) Open-label, phase II clinical trial C209 [13]
Other events
Probability of reversion 1 (0.30) Placebo-controlled phase II clinical trial C208 [12]
Probability of death MDR-TB, no cure 2.21 [34, 35]
MDR-TB, cure 0.32 [34, 35]
XDR-TB, no cure 2.69 [34, 35]
XDR-TB, cure 0.39 [34, 35]
Treatment effect
Hazard ratio of bedaquiline (sputum culture conversion) 2.44 (0.57) Placebo-controlled phase II clinical trial C208 [12]
Hazard ratio of bedaquiline (relapse) 0.32 (0.25) Placebo-controlled phase II clinical trial C208 [12]
Hazard ratio (XDR-TB) 0.40 (0.11) Open-label, phase II clinical trial C209 [13]
Estoniaa Russiab South Africaa Perua Chinaa Philippinesa Indiaa
Probability of loss to follow-up, % (SE) 1.4 (4.1) 1.5 (0.3) 1.4 (0.4) 1.5 (0.8) 0.6 (0.7) 3.4 (1.6) 1.2 (0.6)
SOURCE: (a): [14]; (b): [15]
BR background regimen, MDR-TB multidrug-resistant tuberculosis, SE standard error, XDR-TB extensively drug-resistant tuberculosis
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since the price was unavailable in the countries evalu-
ated at the time of this analysis. The preferred BR regi-
men for this analysis included ethionamide, ofloxacin,
pyrazinamide, ethambutol, and cycloserine, based on the
C208 study [12]. The cost of monitoring patients while
on treatment was dependent on time spent on each
treatment, the phase of treatment (intensive vs. continu-
ous), and the range of clinical tests required. Costs were
sourced from publically available country-specific tariffs
(Table 2). Both costs and benefits were discounted at an-
nual rates recommended by local guidelines (China:
6.0%; Peru: 3.0%; and Estonia, Russia, South Africa,
India, and the Philippines: 5.0%) [27–29].
Health state outcomes
The primary patient outcomes assessed were DALYs
averted. The percentage of patients with cure (defined
as five consecutive negative cultures from samples
collected at least 30 days apart in the final 12 months
of treatment) [13], and the number of patients who
acquired additional resistance (acquisition of XDR-TB)
were also calculated. The primary cost outcomes con-
sisted of direct healthcare costs only, and excluded
treatment acquisition costs.
Price threshold analysis
According to WHO recommendations, three times the
per capita gross domestic product (GDP) is the threshold
cost per DALY where an intervention can be considered
cost-effective [30]. Threshold analysis was conducted to
determine the price range at which the addition of beda-
quiline to BR would be cost-effective in each country
setting at both one times the per capita GDP and three
times the per capita GDP.
In addition, a probabilistic sensitivity analysis (PSA) was
conducted to assess the likelihood of bedaquiline plus BR
being cost-effective versus BR alone at prices ranging from
50% of the lowest price at which the drug would meet the
minimum standard for the WHO CE threshold, to double
the highest price. Details of the PSA and the probabilistic
distributions can be found in Additional file 2: Table S2.
Results
Base-case clinical outcomes
Over a 10-year time horizon, treatment with bedaquiline
plus BR resulted in higher DALYs averted, compared
with BR alone. The highest incremental change in DALYs
was observed in China where the introduction of bedaqui-
line to the BR was associated with just 8.87 DALYs per
Table 2 Cost and disability weight inputs for the high burden countries analyzed, US$ 2013a
Parameter Country
Estonia Russia South Africa Peru China Philippines India
Cost of treatment per month, US$ [source]
Cost of BR (intensive) 141 [20, 25] 273 [18] 167 [25, 36] 149 [22] 78 [23] 134 [25] 95 [37]
Cost of BR (continuation) 78 [20;25] 183 [18] 49 [25, 36] 71 [22] 26 [23] 88 [25] 40 [37]
Cost of monitoring per month, US$ [source]
Bedaquiline + BR Intensive phase 109 [20] 122 [19] 81 [26] 81 [21] 63 [23] 65b 44 [38, 39]
Continuation phase 98 [20] 94 [19] 64 [26] 70 [21] 55 [23] 595b 36 [38, 39]
BR only Intensive phase 101 [20] 100 [19] 65 [26] 68 [21] 60 [23] 59b 43 [38, 39]
Continuation phase 90 [20] 72 [19] 48 [26] 57 [21] 52 [23] 53b 35 [38, 39]
Cost of inpatient and outpatient care, US$ [source]
Cost of hospitalization for initial MDR-TB per day 268 [24] 231 [18] 84 [26] 55 [21] 38 [24] 20 [24] 16 [30]
Cost of outpatient care for
initial MDR-TB
No. of consultation per month
(mean)/unit cost
1/41 [24] 1/36 [24] 1/17 [26] 1/11 [21] 1/9 [24] 1/6 [24] 1/3 [30]
No. of TB nurse home visits per
month (mean)/unit cost
28/1 [24] 28/0 [24] 28/NA [26] 28/NA [21] 28/NA [24] 28/NA [24] 28/NA [30]
Disability weights (mean) by health state for all countries analyzed
Active TB 0.331 [16]
Culture converted TB (first year) 0.170 [16]
Culture converted TB (subsequent year) 0.170 [16]
Lost to follow-up 0.331 (Assumed equal to the active MDR-TB state)
Treatment complete and cured 0 (Assumed equal to the general population [41])
Death 1
BR background regimen, MDR-TB multidrug-resistant tuberculosis, NA Not available, US United States
aAll costs have been converted and inflated to 2013 US$
bSOURCE: local hospital
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patient compared to 11.86 DALYs per patient with BR
alone. This represents a 25.15% reduction in DALYs per
patient (Table 3).
Addition of bedaquiline to the BR resulted in a higher
percentage of patients experiencing successful outcomes
(cured or treatment completed) compared with BR alone.
Incremental change in successful outcomes ranged from
51.62% in China (where the introduction of bedaquiline
was associated with an increase in successful outcomes
from 31.16% to 47.25%) to 60.78% in the Philippines
(where the introduction of bedaquiline was associated
with an increase in successful outcomes from 17.85% to
28.69%) (Table 3).
In the high- and upper middle-income countries (Estonia,
Russia, South Africa, Peru and China), between 31.34% and
40.80% fewer cases of acquired resistance were observed
when bedaquiline was added to the BR compared with BR
alone. China saw a 31.34% reduction, with 52.90 cases
of acquired resistance when bedaquiline was added to
the BR, versus 77.04 with BR alone. South Africa saw
a 40.8% reduction, with 28.20 cases of acquired resist-
ance when bedaquiline was added to the BR, versus
47.58 with BR alone (Table 3).
In the lower-middle income countries (India and the
Philippines), the introduction of Bedaquiline to the BR was
also associated with fewer cases of acquired resistance.
India saw a reduction of 31.61%, with 1,274 cases of
acquired resistance when bedaquiline was added to the BR,
versus 1862.89 with BR alone (Table 3). The Philippines
saw a reduction of 32.22%, with 0.5 cases of acquired resist-
ance when bedaquiline was added to the BR, versus 0.73
with the BR alone.
A sensitivity analysis evaluating the outcomes of treat-
ment with bedaquiline in a cohort of XDR-TB patients
only, demonstrated that bedaquiline was associated with
greater DALYs averted in this patient group (Additional
file 3: Table S3).
Cost analysis
Although outpatient care and monitoring costs were
increased when bedaquiline was added to the BR com-
pared with BR alone, reductions in hospitalization costs
were observed in all settings, resulting in total healthcare
cost offsets compared with BR alone (Table 4). Addition
of bedaquiline to BR resulted in savings to healthcare
costs compared with BR alone in all countries analyzed,
with the highest impact expected in Russia (US$194
million) and South Africa (US$43 million) (Table 4).
Price threshold analysis
The price per regimen of bedaquiline for which beda-
quiline would be cost-effective (according to the WHO
Table 3 Total and incremental results (bedaquiline plus BR versus BR) in the high burden countries analyzed
Estonia Russia South Africa Peru China Philippines India
Cohort
Populationa, cases (n) 38 6,537 6,494 564 826 11 20,763
Estimated Total DALYs, avoided
Bedaquiline + BR 438.41 72,824.26 78,816.95 8,318.51 7,329.94 152.50 299,598.12
BR only 554.29 90,479.07 96,530.04 10,475.26 9,792.45 177.64 384,990.40
Estimated DALYs per patient, avoided
Bedaquiline + BR 11.54 11.14 12.14 14.75 8.87 13.86 14.43
BR only 14.59 13.84 14.86 18.57 11.86 16.15 18.54
Incremental change in DALYs (bedaquiline + BR vs. BR)
(%, relative to bedaquiline)
-20.90 -19.51 -18.35 -20.59 -25.15 -14.16 -22.18
Patients with successful outcomes (%)
Bedaquiline + BR 40.66 38.67 36.50 40.09 47.25 28.69 42.76
BR only 26.29 24.83 23.55 25.88 31.16 17.85 27.97
Incremental change in successful outcomes (bedaquiline + BR
vs. BR) (%, relative to bedaquiline)
+54.67 +55.78 +55.02 +54.87 +51.62 +60.78 +52.87
Number of cases of acquired resistance
Bedaquiline + BR 2.16 349.72 28.20 31.88 52.90 0.50 1,274.00
BR only 3.16 512.37 47.58 46.63 77.04 0.73 1,862.89
Incremental change in acquired resistance (bedaquiline + BR vs. BR)
(%, relative to bedaquiline)
-31.59 -31.75 -40.8 -31.62 -31.34 -32.22 -31.61
BR background regimen, DALY disability-adjusted life years
aPopulation cohort: Russia, China, Philippines: New lab-confirmed MDR-TB cases in 2012 [31]; South Africa: Total number of patients started on MDR-TB treatment
in 2012 [31]; Estonia, Peru: laboratory-confirmed MDR-TB cases in 2012 [31]; India: Total number of patients started on MDR-TB treatment in 2013 [2]
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criteria of 3 times GDP per capita) in Estonia, Russia, Peru,
and China ranged between US$23,904-US$203,492. The
range for South Africa was lower at US$29,151-US$72,701,
while the Philippines and India demonstrated a lower
range, at US$6,996-US$20,323 (Table 5). This is reflective
of the low hospitalization costs and the low willingness-to-
pay per DALY in these countries. At these prices, the
probability that bedaquiline would be cost-effective at
thresholds of 3 times GDP per capita (based upon cost per
DALY) ranged from 32% to 94% (Fig. 2).
Discussion
Management of MDR-TB is costly to national TB pro-
grams. In 122 mostly low- and middle-income countries,
accounting for 95% of the global TB burden including
MDR-TB, total spending for TB prevention, diagnosis,
and treatment increased from US$3.3 billion in 2006 to
US$6.3 billion in 2014 (US$3.8 billion for drug-susceptible
TB and US$1.8 billion for MDR-TB); the estimated
required funding for 2015 is US$8 billion [2]. Costs of
managing patients who develop XDR-TB are even higher,
as hospital stays and drug costs greatly increase [31]. Our
study shows that the addition of bedaquiline to a BR
decreased the DALY burden compared with BR alone.
This study demonstrated that addition of bedaquiline to a
BR reduced cases of acquired resistance. The current
model did not account for potential increases in the num-
ber of people being treated due to improvements in diag-
nostic modalities such as molecular diagnostic platforms
like the Xpert ® MTB/Rif and line probe assays (which can
detect drug resistance within 2 days) that have been intro-
duced in the field of MDR-TB [3]. Faster and more
successful treatment of primary cases could reduce sec-
ondary transmission and decrease the number of new
cases of MDR-TB.
The mortality imbalance observed in the C208 trial
was unexplained. Subsequent analysis by an independent
investigator determined that there was no causal rela-
tionship with bedaquiline and a missing = failure analysis
used within the study accounted for these deaths, con-
sidering them as treatment ‘failures’[12]. In addition,
recent data published based on early access (compas-
sionate use) of bedaquiline, suggests a lower mortality
rate than has been observed in clinical trials. In a retro-
spective cohort study of 35 patients treated with beda-
quiline in France, only one patient died (3%), and the
death was considered unrelated to TB or TB treatment
by the investigator [42]. Similarly, an interim analysis of
91 patients treated with bedaquiline in South Africa re-
ported 3 deaths (3.3%), none of which were considered
related to bedaquiline by the investigator [43]. Therefore,
although mortality was included in the model, no mor-
tality difference was assumed between bedaquiline and
BR treatment arms. Although the increased mortality
observed in the bedaquiline arm of study C208 is not
believed to be related to bedaquiline [12, 42, 43], we
nonetheless conducted a scenario analysis to test how
the inclusion of the death would influence the change in
DALY. Results show that if the mortality rates from
study C208 are separately accounted for in the analysis
(instead of lumping the deaths with all those failing
treatment, as was done in the original analysis), the num-
ber of DALY per patient is likely to increase as a result of
the use of bedaquiline (Additional file 3: Table S3). The
likely impact of sputum culture conversion in reducing in-
fectiousness of patients with TB and the potential to
reduce secondary MDR-TB cases is not accounted for.
When transmission rates were included in sensitivity ana-
lyses, bedaquiline was associated with additional health-
care cost savings associated with the reduced number of
cases (data not shown).
Increases in outpatient care costs observed with the
addition of bedaquiline reflected increases in monitoring
costs associated with the implementation of any new
treatment. Addition of bedaquiline to a BR has been
shown to result in faster and higher culture conversion
rates compared with BR alone [13], an outcome that is
likely to result in decreased need for hospitalization.
MDR-TB guidelines in resource-rich settings typically
require that patients be hospitalized during treatment
[32, 40]; however, the rate of hospitalization in low-to-
middle income countries tends to be low [8] and there is
a push in such settings to drive community-based treat-
ment [33]. In low-to-middle income countries where
the majority of MDR-TB patients are managed in
community-based settings, the price at which it is cost-
effective to add bedaquiline to a BR may be very low,
and may be lower than the price thresholds suggested
in this analysis.
The current study expands on the results of a prior
study conducted on behalf of the WHO, by using a com-
prehensive Markov state transition model over a longer
time horizon (10 years, compared with 20 months in the
WHO analysis), and incorporating more detailed transi-
tions and events such as patient-level data to inform the
state transitions, as well as covering additional countries
[7]. The WHO analysis estimated that bedaquiline was
likely to be cost-effective and cost-saving in Peru, Russia,
Estonia, the Philippines, and China, where treatment
and management costs are moderate to high. In low-
income countries with low drug costs and hospitalization,
such as Nepal, addition of bedaquiline to the treatment
regimen was likely to not be cost-effective [7], whereas
in lower middle-income settings in the current study
(the Philippines and India), there was a 32%94% prob-
ability that bedaquiline would be cost-effective (in
terms of cost per DALY). In high-income settings,
such as the UK, previous studies have shown the

































































































































































































































































































































































































































































































































































































Lu et al. BMC Health Services Research  (2017) 17:87 Page 9 of 12
addition of bedaquiline to BR to be cost-effective,
when measuring cost-utilities such as QALYs gained,
and DALYs avoided [9].
The price threshold analysis shown in this study suggests
that prices higher than the price of bedaquiline in a high
income setting, such as the United States, would meet
WHO criteria for cost-effectiveness in several of the coun-
tries analyzed. While these prices may be cost-effective,
many would raise the question as to whether or not such
prices are affordable; in Table 4, the cost offsets (mostly
attributable to savings from reduced hospitalization) show
that in Estonia and Russia, approximately US$30,000 per
patient will be saved with the use of bedaquiline; in South
Africa, Peru, and China, between US$4,201-US$7,337 per
patient; and the Philippines and India, between US$70-
US$1,528. Prices that capture at least the cost-offsets are
not only cost-effective, but arguably, affordable as long as
they result in no net change in health care spending.
While cost-effectiveness is an important measure to
consider when evaluating new health interventions,
budget impact and value for innovation for the first
new treatment for tuberculosis in 40 years must also
be taken into consideration.
The key strengths of the current study include its
comprehensive health state structure, the use of patient-
level data to inform state transitions, and the extent to
which the model captures WHO guidance on treatment
strategies for MDR-TB.
A limitation of the current analysis was that the clin-
ical data were based on the multinational Phase II study
for bedaquiline [13] and thus may not reflect local varia-
tions in treatment success rates. The study also used UK
specific life tables to calculate DALYs as country specific
life table data were difficult to source. If the UK life
tables are not reflective of the country specific life tables,
this could lead to over/underestimation of the DALY
burden in each country setting. Other limitations of this
study include the fact that possible increases in mortality
due to treatment with bedaquiline have been excluded, as
well as a lack of empirical data on the price of bedaquiline
in the evaluated countries at the time of the analysis.
Conclusions
Treatment with bedaquiline plus BR is expected to im-
prove health outcomes through reduced DALY burden
compared with BR alone. Addition of bedaquiline to BR
resulted in total healthcare cost offsets (excluding treat-
ment acquisition costs). At prices required to satisfy the
WHO CE threshold, the probability that bedaquiline
would be cost-effective was 32%–94% in the high burden
countries analyzed.
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